Skip to main content

Table 1 List of approved ATP-competitive inhibitors and respective indications

From: Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy

First generation
Imatinib First-line and second/subsequent-linea, all disease phases
Second generation
Dasatinib First-line and second/subsequent-line, all disease phases
Nilotinib First-line and second/subsequent-line, CP and AP only
Bosutinib Third-line or when imatinib, dasatinib or nilotinib are not considered appropriate, all disease phases
Third generation
Ponatinib Second/subsequent-line if T315I+ or when no other TKI is considered appropriate, all disease phases
  1. abeing the weaker of all, imatinib is rarely considered as second/subsequent line option especially in case of resistance